If you cannot hear sound, please make sure the volume on the video play bar is turned on or that sound/volume is turned on for your browser or device.
This session was recorded on Wednesday, May 8, 2024
Unlocking Hope: From Gene Editing to Immune Revolution
The implementation of CAR T-cell therapy as a standard of care in British Columbia marks a significant advancement in cancer treatment accessibility for both pediatric and adult patients. Internationally, the approval of the world's first CRISPR-Cas9 genome editing therapies for sickle cell disease in the UK and US represents a major milestone in the field of gene therapy. In this session, we will explore how gene and immune engineering is transforming precision medicine, offering new hope for patients with rare genetic conditions and cancer. Join us to discover how these innovative approaches are paving the way for breakthroughs in medical science.
SPEAKERS
Saad Kenderian
Assistant Professor of Medicine, Immunology and Oncology
Mayo Clinic College of Medicine and Science
Megan Levings
Canada Research Chair in Engineered Immune Tolerance, BCCHR Lead, Childhood Diseases Theme
BC Children’s Hospital Research Institute
Kevin Song, MD FRCPC
Medical Director of the Leukemia / Bone Marrow Transplant Program of British Columbia and Clinical Professor
Department of Medicine in the University of British Columbia (UBC)